Ballif Blake C, Rorem Emily A, Sundin Kyle, Lincicum Matt, Gaskin Shannon, Coppinger Justine, Kashork Catherine D, Shaffer Lisa G, Bejjani Bassem A
Signature Genomic Laboratories, LLC, Spokane, Washington, USA.
Am J Med Genet A. 2006 Dec 15;140(24):2757-67. doi: 10.1002/ajmg.a.31539.
The advent of microarray-based comparative genomic hybridization (array CGH) promises to revolutionize clinical cytogenetics because of its ability to rapidly screen the genome at an unprecedented resolution. Yet, the ability of array CGH to detect and evaluate low-level mosaicism is not known. Our laboratory has analyzed over 3,600 clinical cases with the SignatureChip which we developed for the detection of microdeletions, microduplications, aneuploidy, unbalanced translocations, and subtelomeric and pericentromeric copy number alterations. Here, we report 18 cases of mosaicism detected by array CGH in a routine diagnostic setting, 14 of which were not known to us at the time of the analysis. These 14 cases represent approximately 8% of all abnormal cases identified in our laboratory. For each case, fluorescence in situ hybridization (FISH) analysis was performed on PHA-stimulated cultures after mosaic chromosome abnormalities were suspected by array CGH. In all cases, FISH confirmed the mosaic chromosome abnormalities which included a variety of marker chromosomes, autosomal trisomies, terminal and interstitial deletions, and derivative chromosomes. Interestingly, confirmatory FISH analyses on direct blood smears indicated that the percentage of abnormal cells in unstimulated cultures was in some cases different than that found in PHA-stimulated cells. We also report the detection of a previously unsuspected case of an isochromosome 12p (associated with Pallister-Killian syndrome) by array CGH using genomic DNA extracted from peripheral blood. These results support a growing body of data that suggests that stimulated peripheral blood cultures likely distort the percentage of abnormal cells and may, for some chromosome abnormalities, make their detection unlikely by conventional analysis. Thus, array CGH, which is based on genomic DNA extracted directly from uncultured peripheral blood, may be more likely to detect low-level mosaicism for unbalanced chromosome abnormalities than traditional cytogenetic techniques.
基于微阵列的比较基因组杂交技术(阵列比较基因组杂交,array CGH)的出现有望给临床细胞遗传学带来变革,因为它能够以前所未有的分辨率快速筛查整个基因组。然而,阵列比较基因组杂交检测和评估低水平嵌合体的能力尚不清楚。我们实验室使用我们开发的SignatureChip分析了超过3600例临床病例,该芯片用于检测微缺失、微重复、非整倍体、不平衡易位以及端粒和着丝粒周围的拷贝数改变。在此,我们报告在常规诊断环境中通过阵列比较基因组杂交检测到的18例嵌合体病例,其中14例在分析时我们并不知晓。这14例病例约占我们实验室鉴定出的所有异常病例的8%。对于每一例病例,在通过阵列比较基因组杂交怀疑存在嵌合染色体异常后,对PHA刺激的培养物进行荧光原位杂交(FISH)分析。在所有病例中,FISH均证实了嵌合染色体异常,包括各种标记染色体、常染色体三体、末端和中间缺失以及衍生染色体。有趣的是,对直接血涂片进行的验证性FISH分析表明,在某些情况下,未刺激培养物中异常细胞的百分比与PHA刺激细胞中发现的不同。我们还报告了通过阵列比较基因组杂交,使用从外周血中提取的基因组DNA检测到一例先前未被怀疑的12号等臂染色体(与帕利斯特 -基利安综合征相关)病例。这些结果支持了越来越多的数据,表明刺激的外周血培养物可能会扭曲异常细胞的百分比,并且对于某些染色体异常,可能会使传统分析无法检测到它们。因此,基于直接从未培养的外周血中提取的基因组DNA的阵列比较基因组杂交,可能比传统细胞遗传学技术更有可能检测到不平衡染色体异常的低水平嵌合体。